reports
LACROIX announces its project to exit North America by the end of 2025...
LACROIX announces its project to exit North America by the end of 2025, as part of a strategic refocus on its strongest and highestpotential activities. In Q1 2025, revenue declined by 10.4% on a like-for-like basis. 15/05/2025 LACROIX announces its project to exit North America by the end of 2025, as part of a strategic refocus on its strongest and highest-potential activities In Q1 2025, revenue declined by 10.4% on a like-for-like basis, impacted by ongoing challenging market conditions in the Electronics activity, while strong momentum continued in the Environment activity The 202...
LACROIX annonce son projet de sortie de l’Amérique du Nord d’ici fin 2...
LACROIX annonce son projet de sortie de l’Amérique du Nord d’ici fin 2025, en vue d’un recentrage sur ses activités les plus solides et à fort potentiel. Au 1 er trimestre 2025, un chiffre d’affaires en repli de 10,4% à périmètre constant. 15/05/2025 LACROIX annonce son projet de sortie de l’Amérique du Nord d’ici fin 2025,en vue d’un recentrage sur ses activités les plus solides et à fort potentiel Au 1er trimestre 2025, un chiffre d’affaires en repli de 10,4% à périmètre constant, marqué par une conjoncture toujours difficile sur Electronics et la poursuite d’une forte dynamique sur En...
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fi...
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders,...
GENFIT : Publication du rapport de performance extra-financière 2025 (...
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication de son rapport de performance extra-financière 2025 (exercice 2024). Depuis 2022, GENFIT publie un rapport de performance extra-financière détaillé en réponse à l’intérêt croissant des actionnaires ins...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
MaaT Pharma 1Q25 reiterates pipeline timelines, cash runway into Octob...
MaaT reported 1Q25 results with revenues of € 1.1m (1Q24 € 0.8m), and a cash position of € 24.4m (YE24: € 20.2m), which provides a cash runway into October 2025. Pipeline timelines were reiterated and we look forward to phase 2 data for MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, and hope to learn more about the company's progress with respect to partnering discussions for MaaT013 in aGvHD in Europe as we approach MAA submission in June 2025. We reite...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 A...
MaaT reported additional results from the exploratory single arm phase 1b trial of MaaT033 in ALS, and we view the slower disease progression observed with MaaT033 as encouraging, though we also note the small patient numbers and single arm nature of the trial. ALS is a difficult condition, where many drugs have failed to show slowing of disease progression. As such, MaaT033's early results are promising, and the company is seeking partners focussed on ALS to progress this program. We reiterate ...
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise ...
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication dans l’édition du Bulletin des Annonces Légales Obligatoires n° 55 du 7 mai 2025 de son avis de réunion valant convocation à l’Assemblée Générale Mixte qui se déroulera le 17 ju...
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability...
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 7, 2025 French legal announcements bulletin n°55 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 17, 2025, at 10:00 am (CET), at...
GENFIT to Present Latest ACLF Research at EASL Congress 2025
GENFIT to Present Latest ACLF Research at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community. I. Poste...
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress...
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 5 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui sa participation au Congrès 2025 de l’EASL1 avec six posters présentant notamment les derniers travaux de recherche sur l'ACLF, et plusieurs événements témoignant de l'importance croissante de l'ACLF au sein de la communauté des...
GENFIT : Mise à disposition du Document d’Enregistrement Universel 202...
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du Rapport Annuel Form 20-F 2024 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 29 avril 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le dépôt de son Document d’Enregistrement Universel pour l’exercice 2024 auprès de l’Autorité des Marchés Financiers (AMF ; dépôt n° 25-0331) et de son Rapport Annuel Form 20-F pour l’exercice 20...
GENFIT Announces Publication of the 2024 Universal Registration Docume...
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Secu...
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Hoste
- Jacob Mekhael
MaaT Pharma MaaT034 preclinical data at AACR shows potential in solid ...
MaaT presented new preclinical data for MaaT034 (donor-independent co-cultured microbiome therapy) at the American Association for Cancer Research (AACR) conference, being held 25-30 April in Chicago. The results show the potential for microbiome therapies to improve responses in solid tumours when combined with immune checkpoint inhibitors. Results from a phase 2 investigator-initiated placebo-controlled trial of MaaT013 (microbiome therapy, enema formulation) in combination with checkpoint inh...
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary...
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and significant efficacy in Primary Sclerosing Cholangitis (...
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans...
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025 Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), 28 avril 2025 - GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique spécialisée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui qu'Ipsen présentera les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primi...
Energy Efficiency: LACROIX confirms its growing momentum in the Heatin...
Energy Efficiency: LACROIX confirms its growing momentum in the Heating Networks and Building Management Systems markets. 28/04/2025 Energy Efficiency:LACROIX confirms its growing momentumin the Heating Networks and Building Management Systems markets In a context of energy transition and rising energy costs, the market for remote management solutions for heating networks and Building Management Systems shows strong growth potential.Urbanization, decarbonization, and energy price volatility are reinforcing this momentum, further supported by public policies. In France, the number of dist...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.